| . | ≥ 65 y (115 pts), n (%) . | < 65 y (444 pts), n (%) . | P . |
|---|---|---|---|
| Primary resistance‡ | 12 (10) | 34 (8) | .34 |
| Secondary resistance§ | 14 (12) | 42 (10) | .38 |
| Deaths‖ | 15 (13) | 15 (3) | .0003 |
| Total | 41 (35) | 91 (21) | .0012 |
| . | ≥ 65 y (115 pts), n (%) . | < 65 y (444 pts), n (%) . | P . |
|---|---|---|---|
| Primary resistance‡ | 12 (10) | 34 (8) | .34 |
| Secondary resistance§ | 14 (12) | 42 (10) | .38 |
| Deaths‖ | 15 (13) | 15 (3) | .0003 |
| Total | 41 (35) | 91 (21) | .0012 |
No difference in terms of Primary or Secondary resistance was observed between older and younger patients; on the contrary, failures due to death unrelated to CML progression were significantly more in the older cohort.
European LeukemiaNet (ELN) criteria 25
All analysis were performed according to the intention-to-treat principle.
Primary resistance: no CHR within 3 months; no CyR at 6 months; no PCyR at 12 months; no CCyR at 18 months.
Secondary resistance: loss of CHR; loss of CCyR; progression to accelerated or blast phase; additional chromosomal abnormalities in Ph+ cells; new mutations.
Deaths: unrelated to CML progression.